



FLT4

Recombinant Human VEGFR-3 His-Tag, soluble

Catalog No.	CRF113-005 CRF113A CRF113B	Quantity:	5 µg 10 µg 50 µg
Alternate Names:	Vascular endothelial growth factor receptor 3, VEGFR-3, Fms-Like Tyrosine Kinase 4, FLT-4, Tyrosine-protein kinase receptor FLT4		
Description:	Recombinant human soluble VEGFR3 was fused with a C-terminal 6X histidine-tag. The recombinant mature sVEGFR3 is a glycosylated monomeric protein, consisting of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterized by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGFC and VEGFD have been shown to bind and activate VEGFR3. The VEGFR3 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial at later stages of development. It is important for lymphangiogenesis.		
UniProt ID:	P35916		
Gene ID:	2324		
Source:	Insect cells		
Molecular Weight:	110 kDa (761 aa)		
Formulation:	Lyophilized from PBS		
Purity:	> 90% by SDS-PAGE		
Endotoxin Level:	< 1 EU/µg		
Biological Activity:	Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilized recombinant human sVEGFR-3/FLT-4 at 5µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500ng/ml.		
N-terminal Sequence:	DPSGYSMTPPTLNITEESHV		
Reconstitution:	Centrifuge vial briefly prior to opening. Add PBS or medium to the vial to fully solubilize the protein to a concentration ≥ 100 µg/ml.		
Storage & Stability:	Lyophilized protein is stable for 1 year at -20°C to -80°C. Store reconstituted stock solution in working aliquots at -20°C to -80°C. Avoid repeated freeze-thaw cycles.		

Amino Acid Sequence: DPSGYSMTPTLNITEESHVIDTGDSLISCRGQHPLEWAWPGAQEAPATGDKDSEDT
GVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARIEGTTAASSYVFVRDFEQ
PFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLSQSSVLWPDGQEVVWDDRRGMLVST
PLLHDALYLQCETTWDGQDFLSNPFLVHITGNELYDIQLLPRKSLELLVGEKLVNCTVW
AEFNSGVTFDWDYPGKQAERGKWWPERRSQQTHTELSSILTIHNVSQHDLGSYVCKAN
NGIQRFRESTEIVHENPFISVEWLKGPILVATAGDELVKLPVKLAAYPPPEFQWYKDGK
ALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRNLSLELVNVPPQIHEKEASSPS
IYSRHSRQALTCTAYGVPLPLSIQWHWRPWTCPCKMFAQRSLRRRQQDLMPQCRDW
RAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQANVVSAMYKCVVSNKVGQDERLIY
FYVTTIPDGFTIESKPSSEELLEGQPVLSCQADSYKYEHLRWYRLNLSTLHDAHGNPLLL
DCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRSHDKHCH
KKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQLVAGAHAPSIVWYKDERLLEEKSGVD
LADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEHHHHHH

Inhibition of VEGF-C-induced proliferation of primary human dermal lymphatic endothelial cells (HDLEC) by recombinant human soluble FLT-4. VEGF-C (50ng/ml) was preincubated with increasing amounts of soluble receptor for 1h and then added to the cells.



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.